Clinical Trial Update: Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports safety and immunogenicity data for the EN41-UGR7C HIV vaccine. The study sponsored by PX'Therapeutics has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EN41-UGR7C HIV vaccine (EN41-UGR7C)

Snippet

Sponsor: PX'Therapeutics | Conditions: - HIV | Phase 1 | Status: COMPLETED